hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06294847 id: 2021_0025 briefTitle: Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery acronym: UDCA overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-10 date: 2024-03-06 date: 2024-04-11 name: Hopital Foch class: OTHER briefSummary: This study is indicated for patients with extended rhegmatogenous retinal detachment (RRD) (≥ 2 quadrants) with macula OFF lasting 7 days or less, pseudophakic or aphakic, and scheduled to undergo surgical intervention with vitrectomy and gas tamponade in one of the ophthalmology departments participating in the study.
The main objective is to assess the effectiveness of UDCA in visual acuity recovery at 3 months (i.e., the difference between preoperative visual acuity and visual acuity 3 months after surgery) in pseudophakic or aphakic patients who have undergone successful surgical intervention (reattachment of the retina) through vitrectomy and gas tamponade following rhegmatogenous retinal detachment (RRD).
* the control group "Placebo Group," with oral administration of the placebo. conditions: Retinal Detachment studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 120 type: ESTIMATED name: Ursolvan name: Placebo measure: Difference in visual recovery (difference between preoperative and postoperative visual acuity) at 3 months postoperative (after a successful reapplication procedure) of at least 6 letters (ETDRS scale) between the two groups (treatment and placebo) measure: Central Nervous Epithelium (CNE) thickness measure: Automated microperimetry at 1, 3, and 6 months: Macular sensitivity difference between the two groups. measure: Contrast sensitivity measurement using the Clinic CSF2.0 application. measure: Presence/absence of abnormal signs on optical coherence tomography (OCT) images (cysts, folds, membrane, ellipsoid zone, external limiting membrane). measure: Retinal thickness measured by OCT (retinal layers and presence of cysts, layer segmentation and measurement in the central 1 and 3 mm in ETDRS quadrants). measure: Number of macular cones and retinal pigment epithelium (RPE) cells measured by Adaptive Optics at 1, 3, and 6 months with the "Cellularis" device that allows visualization of cones and RPE. measure: Blood test: liver parameters - AST (SGOT), ALT (SGPT), PAL, and γ-GT. measure: Evolution of the best visual acuity measured at Day 0, Day 7, Day 30, Day 60, Day 90, and Day 180: Difference between the treated and placebo groups in the progression curves of visual acuity. measure: Presence of metamorphopsia. measure: Tolerance and occurrence of adverse events. measure: National Eye Institute Visual Functioning Questionnaire-25 (NEIVFQ-25) quality of life questionnaire before surgery, at ±7 days postoperative, and at 3 months postoperative. measure: Correlation between protein levels, bile acids, or other molecular markers in ocular and/or blood fluids and functional and anatomical ocular parameters pre- and post-operatively at different observation times. measure: Correlation between the effective duration of treatment and functional and anatomical outcomes at different observation times. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Cochin city: Paris zip: 75014 country: France name: EYMARD Pauline, Dr role: CONTACT email: pauline.eymard@aphp.fr name: EYMARD Pauline role: PRINCIPAL_INVESTIGATOR lat: 48.85341 lon: 2.3488 facility: Hôpital Foch city: Suresnes zip: 92150 country: France name: Behar Cohen Francine, Pr role: CONTACT phone: 01 46 25 22 75 email: .behar-cohen@hopital-foch.com name: Behar Cohen Francine, Pr role: PRINCIPAL_INVESTIGATOR lat: 48.87143 lon: 2.22929 hasResults: False
nctId: NCT06294834 id: STUDY22010071 id: 90SIMS0010 type: OTHER_GRANT domain: NIDILRR briefTitle: Improving Clinician Capacity to Provide Interventions for Manual Wheelchair Users acronym: SKILL overallStatus: RECRUITING date: 2023-02-22 date: 2026-08-30 date: 2026-12-30 date: 2024-03-06 date: 2024-03-06 name: University of Pittsburgh class: OTHER name: Dalhousie University name: National Institute on Disability, Independent Living, and Rehabilitation Research briefSummary: The objective of this study is to determine the effectiveness of remote manual wheelchair skills training program for clinicians. The study will use three-group approach: intervention with remote feedback (Group 1), control group (Group 2), and structured self-study (Group 3). This demonstrates how the intervention compares not only to a control, but also to the next "best alternative" - therapists sourcing web-based training materials and learning independently. conditions: Wheelchair Skills studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomized, single-blinded, two-period cross-over study design for Groups 1 and 2. Participants will complete baseline assessments and then be randomized to either Group 1 or Group 2. After enrollment for Groups 1 and 2 is complete, participants will be enrolled into Group 3. primaryPurpose: OTHER masking: SINGLE maskingDescription: For therapists, we will use a randomized, single-blinded, two-period cross-over study design for Groups 1 and 2. Participants will complete baseline assessments and then be randomized to either Group 1 or Group 2. After we have completed enrollment for Groups 1 and 2 we will enroll participants into Group 3.
Rehabilitation professionals who are not therapists will be enrolled in Group 4. whoMasked: PARTICIPANT count: 240 type: ESTIMATED name: Part 1 of intervention A - Wheelchair skills training modules name: Part 2 of intervention A - Asynchronous feedback from a remote trainer name: Intervention B: Education on wheelchair provision measure: Change in Wheelchair Skills Test Questionnaire (WST-Q) score measure: Change in Self-Efficacy on Assessing, Training, and Spotting (SEATS) score measure: Change in number of wheelchair users trained measure: Change in quality of wheelchair skills trained measure: Change in rehab professional Wheelchair Skills Test Questionnaire (WST-Q) score measure: Change in rehab professional Self-Efficacy on Assessing, Training, and Spotting (SEATS) score measure: Change in rehab professional quantity of wheelchair users trained measure: Change in rehab professional quality of wheelchair training sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pittsburgh / Rehab Neural Engineering Labs status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15219 country: United States name: Lee Tempest, BS role: CONTACT phone: 412-232-9326 email: tempestml@upmc.edu name: Debbie Harrington, BS role: CONTACT phone: 412-383-1355 email: debbie.harrington@pitt.edu lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06294821 id: 00003845 briefTitle: 4AP to Delay Carpal Tunnel Release (CTR) acronym: CTR overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2027-12 date: 2028-07 date: 2024-03-06 date: 2024-03-12 name: John Elfar class: OTHER briefSummary: The investigators have found recent promising data supporting the use of a currently FDA approved drug, 4-aminopyridine, in the treatment of nerve injury including compression neuropathy. The purpose of this research is determine whether 4-aminopyridine can delay the need for formal surgical release in patients with known carpal tunnel syndrome who would otherwise undergo surgery. conditions: Compression Neuropathy conditions: Carpal Tunnel Syndrome studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 160 type: ESTIMATED name: 4-Aminopyridine name: Placebo measure: Results of symptomatic improvement in the Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ) measure: Results of symptomatic improvement in the Michigan Hand Outcomes Questionnaire (MHQ) measure: Electrodiagnostic improvement following treatment sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06294808 id: 2017-2601 briefTitle: Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC overallStatus: COMPLETED date: 2017-07-17 date: 2020-06-30 date: 2020-06-30 date: 2024-03-06 date: 2024-03-06 name: National Cancer Centre, Singapore class: OTHER name: Singapore General Hospital briefSummary: Clinical outcomes after surgical resection in HCC is a continuum and is clearly related to tumor burden but needs better definition. The researchers describe the use of the "metro ticket" approach to analyze surgical outcomes over the whole spectrum of anatomically resectable HCC to define overall survival including intermediate stage tumors (BCLC B). The analysis the researchers provide in this study enables the clinician to select the optimal surgical resection candidate based on robust long term survival data.
In addition, study compares outcome for open surgery vs laparoscopic surgery, survival outcome for viral and non-viral HCC using Albumin-Bilirubin (ALBI) for more comprehensive study result. conditions: Hepatocellular Carcinoma Resectable studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: RETROSPECTIVE count: 1043 type: ACTUAL measure: 5-year mortality. measure: Concordance of pre-operative radiological and post operative surgical specimen. measure: Agreement between TBI calculated from pre-operative imaging versus those obtained from post-surgical pathological assessment. sex: ALL minimumAge: 21 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Centre, Singapore city: Singapore zip: 168583 country: Singapore lat: 1.28967 lon: 103.85007 facility: Singapore General Hospital city: Singapore zip: 169608 country: Singapore lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06294795 id: 2-2024 briefTitle: Toric Intraocular Lens Implantation in Pediatric Cataract acronym: TILIPC overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-12-31 date: 2024-03-06 date: 2024-03-15 name: Kazakh Eye Research Institute class: NETWORK briefSummary: To evaluate the visual and refractive outcomes after an intraocular lens (IOL) implantation in pediatric eyes with cataract and preexisting corneal astigmatism conditions: Cataract Congenital conditions: Astigmatism conditions: IOL studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: congenital/pediatric cataract surgery name: Non-Toric IOLs name: Toric IOLs measure: Uncorrected (UCDVA) and corrected (CDVA) distance visual acuity measure: Uncorrected (UCNVA) and corrected (CNVA) near visual acuity measure: Refraction measurements measure: Keratometry measurements sex: ALL minimumAge: 6 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Kazakh Eye Research Institute status: RECRUITING city: Almaty zip: 050012 country: Kazakhstan name: Kairat Ruslanuly, MD role: CONTACT phone: +77019008387 email: ruslanuly.kairat@gmail.com name: Zhansaya Sultanbayeva, MD role: CONTACT phone: +77023777735 email: sultanbayeva.zhansaya@gmail.com name: Lukpan Orazbekov, MD role: PRINCIPAL_INVESTIGATOR name: Kairat Ruslanuly, MD role: SUB_INVESTIGATOR name: Zhansaya Sultanbayeva, MD role: SUB_INVESTIGATOR name: Meruert Ashimova, MD role: SUB_INVESTIGATOR lat: 43.25667 lon: 76.92861 facility: Kazakh Eye Research Institute status: RECRUITING city: Astana zip: 010000 country: Kazakhstan name: Gulnaz Kassymbekova, MD role: CONTACT phone: +77478538289 email: GulnazKassymbekova@gmail.com name: Asiya Beisebayeva, MD role: CONTACT phone: +77018333953 name: Aigerim Tuletova, MD role: PRINCIPAL_INVESTIGATOR name: Asiya Beisebayeva, MD role: SUB_INVESTIGATOR name: Gulnaz Kassymbekova, MD role: SUB_INVESTIGATOR lat: 51.1801 lon: 71.44598 hasResults: False
nctId: NCT06294782 id: 36/2022 briefTitle: PrOsPective Cohort Study for STereotactic Arhythmia Radioablation (STAR) of Refractory Ventricular Tachycardia acronym: POPSTAR overallStatus: RECRUITING date: 2022-04-15 date: 2025-02 date: 2025-02 date: 2024-03-06 date: 2024-03-06 name: University of Turin, Italy class: OTHER name: Azienda Unità Sanitaria Locale Reggio Emilia name: IRCCS Sacro Cuore Don Calabria di Negrar name: Fondazione IRCCS Policlinico San Matteo di Pavia briefSummary: This is a multicenter, interventional study. The study will enroll patients that fulfill the inclusion criteria over a 33-month period. Considering the small number of patients who will meet the study criteria, it is also possible to include retrospective patients who already underwent STAR (for instance, as part of a compassionate program) if they meet all the inclusion and exclusion criteria as well as the treatment planning standardized requirements and sign their consent to this trial. All patients prospectively enrolled will undergo a flow of investigations following a standardized approach. ICD programming will be standardized. conditions: Refractory Ventricular Tachycardia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: STereotactic Arhythmia Radioablation (STAR) measure: VT storm and incessant VT measure: adverse events sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Turin status: RECRUITING city: Turin country: Italy name: Gaetano Maria De Ferrari role: CONTACT lat: 45.07049 lon: 7.68682 hasResults: False
nctId: NCT06294756 id: acquealbuleroma1 id: AR1221816703484E type: OTHER_GRANT domain: La Sapienza University, Rome, Italy briefTitle: Sulfureous Water Therapy in Viral Respiratory Diseases acronym: STWandRVD overallStatus: COMPLETED date: 2023-05-30 date: 2023-08-01 date: 2023-09-30 date: 2024-03-06 date: 2024-03-06 name: University of Roma La Sapienza class: OTHER name: Università degli studi di Roma Foro Italico name: Queen Mary University of London name: Bios Prevention Srl briefSummary: The goal of this double-blind, interventional, randomized case-control, pilot trial is to evaluate the effects of active sulfurous (STW) versus placebo (SDW) inhalations on blood test parameters, serum inflammatory cytokines, spirometry data, as well as qualitative and quantitative changes in the nasal microbiome of subjects affected by long Covid.
nctId: NCT06294743 id: C202304001 briefTitle: Posterior Tibia Nerve Neuroprolotherapy for Dysmenorrhea overallStatus: RECRUITING date: 2023-11-23 date: 2025-12-31 date: 2025-12-31 date: 2024-03-06 date: 2024-03-06 name: Taichung Armed Forces General Hospital class: OTHER_GOV briefSummary: The goal of this crossover study is to assessed the treatment efficacy of posterior tibia nerve neuroprolotherapy on dysmenorrhea. The primary outcome is the improvement of Visual Analogue Scale. The main question it aims to answer is:
Participants will be randomly allocated into two groups, Group-1 will receive neuroprolotherapy in the first 2 menstrual cycles followed by oral acetaminophen(500mg) for the subsequent 2 menstrual cycles. Group02 will received oral acetaminophen(500mg) in initial 2 menstrual cycles, followed by receiving neuroprolotherapy for the subsequent 2 menstrual cycles. conditions: Dysmenorrhea conditions: Prolotherapy studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Group-1, posterior tibial nerve neuroprolotherapy will be administered during the first two menstrual cycles, followed by oral acetaminophen (500mg) for the subsequent two menstrual cycles. Conversely.
Group-2, oral acetaminophen (500mg) will be given during the initial two menstrual cycles, followed by a transition to posterior tibial nerve neuroprolotherapy for the last two menstrual cycles. primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Posterior tibial nerve neuroprolotherapy name: Acetaminophen 500Mg Tab measure: Visual Analogue Scale measure: The SF-36v2® Health Survey sex: FEMALE minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Taichung Armed Forces General Hospital status: RECRUITING city: Taichung state: Other (Non US) zip: 41168 country: Taiwan name: Jing-dung Shen, MD role: CONTACT phone: +886958878129 email: jdwhydo@gmail.com name: Jing-dung Shen, MD role: PRINCIPAL_INVESTIGATOR lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06294717 id: AtaturkUPhStudentNeslihanATLI briefTitle: The Effect of Progressive Relaxation Exercises on Physiological Parameters, Pain and Anxiety After Cesarean Section overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-08-01 date: 2024-12-01 date: 2024-03-05 date: 2024-03-05 name: Ataturk University class: OTHER briefSummary: Caesarean section is a surgical procedure that can be performed before or during birth in cases where the life of the mother and fetus is threatened or upon the request of the mother and father. One of the most common problems after cesarean section is abdominal pain. Progressive relaxation exercises are a method that allows certain muscle groups in the body to first contract and then relax. Progressive relaxation exercises have been proven to have positive effects on anxiety. By applying progressive relaxation exercises, the parasympathetic nervous system is activated; Thus, heart and respiratory rate and blood pressure can be kept within normal limits. This study will be conducted to determine the physiological parameters, pain and anxiety levels of progressive relaxation exercises, one of the non-pharmacological methods, on women giving birth by cesarean section. conditions: Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 2 type: ESTIMATED name: Progressive relaxation exercises will be applied. measure: Beck Anxiety Scale measure: Visual Analog Scale (VAS) sex: FEMALE minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06294704 id: 2024/0004 briefTitle: Hybrid Closed Loop Insulin Pump and Bariatric Surgery in Patients With Type 1 Diabetes acronym: PompBariatDT1 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2024-12-31 date: 2024-03-05 date: 2024-04-08 name: Centre Hospitalier Sud Francilien class: OTHER briefSummary: Bariatric surgery is increasingly performed on patients with type 1 diabetes. It exposes these patients to an increased risk of hypoglycemia, including severe hypoglycemia, and of severe episodes of hyperglycemia, beyond the perioperative period. The long-term efficacy and safety of hybrid closed-loop insulin pump in these patients has not yet been published. conditions: Bariatric Surgery conditions: Type 1 Diabetes studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 20 type: ESTIMATED name: bariatric surgery measure: time spent within glycemic target 70-180 mg/dL measure: Time spent in level 1 hyperglycemia (181-250 mg/dL) measure: Time spent in level 2 hyperglycemia (>250 mg/dL) measure: HbA1c measure: Coefficient of variation measure: Time spent in level 1 hypoglycemia (51-70 mg/dl) measure: Time spent in level 2 hypoglycemia (< 50 mg/gdl) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre Hospitalier Sud Francilien city: Corbeil-Essonnes zip: 91106 country: France name: Caroline TOURTE role: CONTACT phone: +33161693150 email: caroline.tourte@chsf.fr lat: 48.60603 lon: 2.48757 hasResults: False
nctId: NCT06294691 id: infusion time & aGVHD-002 briefTitle: Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-11-30 date: 2026-08-31 date: 2024-03-05 date: 2024-03-05 name: Anhui Provincial Hospital class: OTHER_GOV briefSummary: To observe the effect of stem cell infusion on the development of acute graft- versus-host disease (aGVHD) in patients with nonmalignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) conditions: Acute Graft-versus-host Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 198 type: ESTIMATED name: Time of stem cell infusion measure: The cumulative incidence of grade III to IV aGVHD measure: The cumulative incidence of grade II to IV aGVHD measure: The cumulative incidence of neutrophil engraftment at 28 days after transplantation measure: The cumulative incidence of platelet recovery at 100 days after transplantation measure: The cumulative incidence of transplant-related mortality at 180 days after transplantation measure: The cumulative incidence of transplant-related mortality at 360 days after transplantation measure: The cumulative incidence of chronic GVHD at 360 days after transplantation measure: The probability of GVHD-free, relapse-free survival(GRFS) measure: The probability of disease-free survival(DFS) measure: The probability of overall survival(OS) sex: ALL minimumAge: 12 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) city: Hefei state: Anhui zip: 230036 country: China lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06294678 id: infusion time & aGVHD-001 briefTitle: Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-11-30 date: 2026-08-31 date: 2024-03-05 date: 2024-03-05 name: Anhui Provincial Hospital class: OTHER_GOV briefSummary: To observe the effect of stem cell infusion on the development of acute graft-versus-host disease (aGVHD) in patients with malignant hematologic diseases after allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) conditions: Acute Graft-versus-host Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 198 type: ESTIMATED name: Time of stem cell infusion measure: The incidence of grade III to IV aGVHD measure: The incidence of grade II to IV aGVHD measure: The cumulative incidence of neutrophil engraftment at 28 days after transplantation measure: The cumulative incidence of platelet recovery at 100 days after transplantation measure: The cumulative incidence of transplant-related mortality at 180 days after transplantation measure: The cumulative incidence of transplant-related mortality at 360 days after transplantation measure: The cumulative incidence of chronic GVHD at 360 days after transplantation measure: The probability of GVHD-free, relapse-free survival(GRFS) measure: The probability of disease-free survival(DFS) measure: The probability of overall survival(OS) sex: ALL minimumAge: 12 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) city: Hefei state: Anhui zip: 230036 country: China lat: 31.86389 lon: 117.28083 hasResults: False